ERBB2 and breast cancer: The GIM 13-AMBRA study is a cohort, real-world study which collected data from more than 900 HER2- metastatic breast cancer patients in Italy from diagnosis until death, or data censoring, and so far, represents a priceless opportunity to collect insights useful for future trials.